Pular para o conteúdo
Menu
Mix Vale

Novo Nordisk projects oral weight-loss drugs to exceed a third of GLP-1 market by 2030 amid consumer shifts

Luís Pereira
Por 5 min de leitura
Compartilhe
logotipo da empresa farmacêutica Novo Nordisk
Foto: logotipo da empresa farmacêutica Novo Nordisk - reprodução

Oral weight-loss medications are now projected to capture a third or more of the global GLP-1 market by 2030, a significantly higher percentage than originally forecast by Novo Nordisk. This updated outlook reflects a deepening understanding of consumer behavior within the rapidly evolving obesity treatment landscape.

Publicidade

The revised projection was shared by Ludovic Helfgott, executive vice president for product strategy and portfolio at Novo Nordisk, during the J.P. Morgan Healthcare conference in January 2025. This statement signals a notable shift from the company’s initial assumptions, which primarily favored injectable treatments.

Publicidade

Helfgott conveyed that while earlier models depicted injectables as market dominators and pills as a minor segment, the company’s current assessment points to a robust future for oral options. This strategic reevaluation underscores the potential for a substantial expansion of the pill market.

Updated market vision: Oral drugs’ rising prominence

The pharmaceutical giant’s initial market assumptions heavily weighted injectable GLP-1 therapies, envisioning a more limited role for oral formulations. However, ongoing market dynamics and patient feedback have prompted a comprehensive reevaluation of these projections for the coming years.

Speaking to industry observers, Helfgott confirmed the revised internal belief that oral GLP-1 medications could realistically constitute up to a third or even more of the overall market. This shift suggests a pivotal moment in how these life-changing treatments are perceived and utilized globally.

Consumer behavior drives reevaluation

The pharmaceutical group’s updated perspective stems from a refined understanding of consumer engagement in what is increasingly recognized as a consumer-driven obesity market. A significant portion of patients, particularly in the United States, are paying for these treatments directly out of pocket, influencing demand and preference.

Novo Nordisk introduced an oral daily version of Wegovy to the U.S. market in early January 2025, priced at an initial $149 per month. This launch strategically positions the company to tap into broader patient demographics and address diverse access needs, expanding the reach of effective weight management solutions.

Publicidade

Expanding treatment access and reach

The newly launched oral version of Wegovy is expected to expand treatment accessibility to patient groups previously underrepresented in GLP-1 usage. This includes men and younger patients, who may find oral administration more appealing or convenient than injections.

Some potential users of the recently launched pill do not fully acknowledge obesity as a chronic disease or may be “in denial” about their condition. Helfgott noted that the oral format “opens categories of the population” that have historically been hesitant to engage with injectable treatments due to stigma, fear of needles, or other personal preferences, fostering a more inclusive treatment landscape.

Analyst perspectives and market size

The reevaluation by Novo Nordisk occurs as financial analysts continue to debate the long-term role and market penetration of oral GLP-1s. While some estimates have been more conservative, the industry is closely watching market performance data to gauge future trends.

Last year, analysts from TD Cowen projected that pills would account for approximately 15% of global obesity drug sales by 2030, within a market estimated to reach $150 billion. Novo Nordisk’s more optimistic internal forecast highlights a potential divergence in market expectations.

AI insights into patient engagement

In late 2024, Novo Nordisk conducted extensive patient segmentation and targeting exercises to better understand its prospective user base. These efforts utilized advanced artificial intelligence models and other analytical tools to categorize new potential GLP-1 users.

The company identified six or seven distinct behavioral groups among these potential patients. This in-depth analysis is crucial for developing tailored marketing strategies and improving patient education, ultimately helping the pharmaceutical company comprehend the diverse motivations that prompt individuals to start weight-loss medication.

The strategic shift in GLP-1 landscape

The pharmaceutical industry is observing a significant strategic shift, particularly regarding the development and deployment of oral GLP-1 treatments. The convenience and reduced invasiveness of pills are powerful drivers in patient adoption, potentially broadening the market significantly beyond what was initially envisioned for injectables alone.

This enhanced understanding of patient preferences and market dynamics is not just about sales; it reflects a broader commitment to making obesity treatments more accessible and acceptable to a wider range of individuals. As more players enter the GLP-1 arena, the ability to cater to diverse patient needs through varied administration routes will be a key differentiator.

The competitive landscape for GLP-1 medications continues to intensify, with several pharmaceutical companies investing heavily in both oral and injectable formulations. This competition is expected to accelerate innovation and potentially drive down costs over time, making these therapies more attainable for a global patient population.

This strategic re-calibration by Novo Nordisk underscores a proactive approach to a rapidly expanding and increasingly consumer-centric market, positioning oral GLP-1s as a cornerstone of future obesity management. The implications extend to healthcare providers and insurers, who must adapt to these evolving treatment preferences.

Notícias relacionadas